MF
TVTX icon

Magnetar Financial’s Travere Therapeutics TVTX Stock Holding History

Magnetar Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,529
Closed -$261K – 545
2019
Q1 		$261K Buy
+11,529
New +$255K 0.01% 337

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Magnetar Financial's TVTX Position: Q2 2019 in Review

Magnetar Financial sold out of Travere Therapeutics (TVTX) in Q2 2019, closing a stake of 11,529 shares — an estimated $261K sold.

Magnetar Financial first reported a position in TVTX in Q1 2019 and held it in 1 quarter. The position peaked at $261K in Q1 2019. 122 funds tracked by Wall St. Rank hold TVTX as of Q2 2019.

  • Magnetar Financial reported no remaining Travere Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Magnetar Financial sold 11,529 Travere Therapeutics shares in Q2 2019, an estimated $261K.
  • Magnetar Financial first reported a position in Travere Therapeutics in Q1 2019 and held it in 1 quarter.
  • Magnetar Financial's Travere Therapeutics position peaked at $261K in Q1 2019.
  • 122 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2019.

Based on Magnetar Financial's 13F filing for Q2 2019, filed 14 Aug 2019.